Gregory Weaver - Oct 1, 2025 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Financial Officer
Signature
/s/ Gregory Weaver as Attorney-in Fact
Stock symbol
ALT
Transactions as of
Oct 1, 2025
Transactions value $
$0
Form type
4
Date filed
10/3/2025, 04:24 PM
Previous filing
Mar 14, 2025
Next filing
Nov 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WEAVER GREGORY L Chief Financial Officer C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG /s/ Gregory Weaver as Attorney-in Fact 2025-10-03 0001251779

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +167K $0.00 167K Oct 1, 2025 Common Stock, par value $0.0001 167K $3.87 Direct F1
transaction ALT Restricted Stock Units Award $0 +57.9K $0.00 57.9K Oct 1, 2025 Common Stock, par value $0.0001 57.9K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested
F3 The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.